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Abstract  
BACKGROUND: Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease that worsens during the 
course of the disease and can cause disability. Early RA refers to the onset of symptoms within the past 3 
months. In RA, increased levels of mediators of inflammation may cause arterial stiffness consequently leading to 
arterial hypertension.  
AIM: The aim of this cross-sectional study was to assess the prevalence of asymptomatic arterial hypertension in 
early RA patients as well as the correlation with parameters of inflammation. 
METHODS: One hundred and seventy-nine early RA patients diagnosed in agreement with ACR/EULAR 
(American College of Rheumatology/ European League against Rheumatism) 2010 criteria were consecutively 
included in the study. CRP (C-reactive protein) and anti CCP (Antibodies to cyclic citrullinated peptides) serum 
levels, WBC (white blood cells) count and ESR (Erythrocyte sedimentation rate), likewise DAS-28 (28-joint 
disease activity score) were determined in all included patients. Parametric tests were used to compare the 
characteristics of the groups and to test the correlation of the variables. 
RESULTS: Statistical data analysis revealed that a majority of the patients were females (n = 141; 78.7%); the 
mean age at RA onset was 49.13 ± 12.13 years. Overall prevalence of hypertension was 44.13 % (n = 79). In 
comparison with the normotensive patients, the hypertensive patients were older and had significantly higher 
values of CRP, ESR, anti-CCP and DAS-28. A highly significant positive correlation between all the study 
parameters and systolic and diastolic blood pressure was observed.  
CONCLUSION: Presence of significantly higher values of CRP, ESR, anti-CCP and DAS-28 in hypertensive 
patients indicate that inflammation is associated with an increased risk of hypertension. In this context, early 
screening for arterial hypertension and adequate therapeutic measures should be considered in early RA patients. 
 
 
 
Introduction 
 
Rheumatoid arthritis (RA) is a chronic 
systemic inflammatory disease characterized by joint 
and multiple organ systems involvement that worsens 
during the course of the disease and can cause 
disability [1, 2]. Early RA is defined as the onset of 
symptoms of joint (typically poliarticular) pain, stiffness 
or swelling within the past 3 months [3, 4]. 
Increased risk for adverse outcomes in 
patients with RA that can partially be attributed to 
cardiovascular (CV) disease has been reported by 
several studies [5-9]. In RA, increased levels of 
mediators of inflammation may cause arterial stiffness 
and increase peripheral resistance, consequently 
leading to arterial hypertension, thus providing a 
potential link between inflammation and arterial 
hypertension in RA [10-14]; in addition, physical 
inactivity, medications used in RA and co-morbidities 
may contribute to blood pressure increments [15, 16]. 
Early treatment of RA may minimize the 
impact of RA associated factors in arterial 
hypertension development and thus may improve 
short- and long-term outcome of RA [4, 17]. 
To date, there is limited information available 
about the prevalence of arterial hypertension in early 
RA patients. Thus, the main objective of the present 
cross-sectional study was to assess the prevalence of 
arterial hypertension in early RA patients. In addition, 
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the correlation of clinical and laboratory parameters of 
inflammation with systolic and diastolic arterial blood 
pressure was assessed. 
 
 
Material and Methods 
 
One hundred and seventy-nine early RA 
patients diagnosed in agreement with ACR/EULAR 
2010 criteria [18] were consecutively included in this 
cross-sectional study. The study was conducted in the 
Rheumatology department at the University Clinical 
Center of Kosovo, between April 2013 and May 2016. 
Blood pressure (BP) measurements were 
performed by the physician with the patient sitting in a 
chair for at least ten minutes. Mean values of three BP 
measurements obtained five minutes apart were 
recorded. Arterial hypertension was defined as 
systolic BP equal to or greater than 140 mmHg, 
and/or diastolic BP equal to or greater than 90 mmHg. 
According to the BP values, the patients were 
categorized into two groups: hypertensive patients (n 
= 79) and normotensive patients (n = 100).  
Venous blood samples were collected after an 
overnight fasting period of 10-12 hours. White blood 
cells (WBC) count and C-reactive protein (CRP) 
concentration measurements were performed at the 
main hospital laboratory, while auto antibodies to 
cyclic citrullinated peptides (anti-CCP) were measured 
by a licensed private laboratory. Enzyme-linked 
immunosorbent assay (ELISA) kits were used to 
measure CRP and anti-CCP concentrations. 
Westergren erythrocyte sedimentation rate (ESR) was 
expressed as millimeters in one hour (mm/h), 
The Disease Activity Score-28 (DAS-28), an 
index containing a 28-joint count for tenderness, 
swelling, inflammation (CRP or ESR) and visual 
analogue scale (VAS) was used to describe the 
severity of RA [19]. 
Local ethical committee approved the study 
protocol prior to the initiation of the study and all the 
participants gave written informed consent. 
The study variables were evaluated for the 
normality of the distribution using the Kolmogorov-
Smirnov test. As the variables were normally 
distributed, independent samples t-test was performed 
to compare the characteristics of the groups while 
Pearson’s correlation test was performed to test the 
correlation between the study variables. Data are 
presented as mean ± standard deviation (S.D.) or 
proportions, as appropriate. A p value less than 0.05 
was considered statistically significant. All statistical 
analyses were performed using SPSS 16.0 software 
(SPSS Inc., Chicago, USA).  
 
Results 
 
The demographic and laboratory 
characteristics of hypertensive and normotensive 
early RA patients are summarized in Table 1. Data 
analysis revealed that 141 (78.7%) patients were 
females while 38 (21.3%) patients were males; the 
mean age at RA onset was 49.13 ± 12.13 years 
(range, 25-80). The prevalence of hypertension in this 
sample of patients was 44.13 % (n = 79). The patients 
with early RA were categorized into two groups 
according to BP values. Comparison of the means ± 
SD of hypertensive patients vs. normotensive patients 
with independent samples t-test demonstrated 
significantly higher values of CRP, ESR, anti-CCP and 
DAS-28 in hypertensive patients (p < 0.001). In 
comparison with the normotensive patients, the 
hypertensive patients were older (p = 0.005); 
however, there were no significant differences 
between the groups in gender (p = 0.714), place of 
residence (p = 0.095) or WBC count.  
Table 1: Demographic and laboratory characteristics of the 
patients with early rheumatoid arthritis  
 All (n = 179) Hypertensive 
patients 
(n = 79) 
Normotensive 
patients (n = 100) 
p value 
Age (years) 49.13 ± 12.13 52.03 ± 12.16 46.85 ± 11.67 p = 0.005 
Gender (F/M) 141/38 61/18 80/20 p = 0.714 
Place of residence 
(Village/City) 
100/79 50/29 50/50 p = 0.095 
CRP (mg/dl) 37.87 ± 35.71 56.79 ± 41.46 22.92 ± 20.66 P < 0.001 
ESR (mm/h) 39.76 ± 25.97 51.91 ± 28.91 30.17 ± 18.54 P < 0.001 
Anti-CCP (U/dml) 207.49 ± 165.99 303.95 ± 167.65 131.30 ± 117.76 P < 0.001 
DAS-28 5.43 ± 1.12 6.19 ± 0.99 4.82 ± 0.79 P < 0.001 
WBC  8.81 ± 3.57 9.21 ± 3.74 8.49 ± 3.41 p  = 0.186 
CRP = C-reactive protein; ESR = Erythrocyte sedimentation rate; Anti-CCP = Antibodies to 
cyclic citrullinated peptides; DAS-28 = 28-joint disease activity score; WBC white blood 
cells. 
 
When all the early RA patients were 
considered, as presented in Table 2, a highly 
significant positive correlation between all the study 
parameters and systolic and diastolic blood pressure 
was observed (p < 0.01).  
Table 2: Pearson’s correlation analysis between clinical and 
laboratory parameters and arterial blood pressure in patients 
with early rheumatoid arthritis categorized according to 
presence or absence of arterial hypertension (r) 
 All study subjects (179) Hypertensive patients  
(n = 79) 
Normotensive patients  
(n = 100) 
 Systolic AP 
(mm/Hg) 
Diastolic AP 
(mm/Hg) 
Systolic AP 
(mm/Hg) 
Diastolic AP 
(mm/Hg) 
Systolic AP 
(mm/Hg) 
Diastolic AP 
(mm/Hg) 
Age 
(years) 
0.303** 0.272** 0.176 0.125 0.279** 0.243* 
CRP 
(mg/dl) 
0.498** 0.490** 0.288* 0.268* 0.135 0.065 
ESR 
(mm/h) 
0.481** 0.505** 0.317** 0.388** 0.218* 0.176 
Anti-CCP 
(U/dml) 
0.493** 0.473** 0.174 0.231* 0.095 -0.107 
DAS-28 0.695** 0.698** 0.474** 0.578** 0.380** 0.223* 
WBC  0.204** 0.212** 0.223* 0.283* 0.208* 0.152 
*p < 0.05; **p < 0.01; AP = Arterial pressure; CRP = C-reactive protein; ESR = Erythrocyte 
sedimentation rate; Anti-CCP = Antibodies to cyclic citrullinated peptides; DAS-28 = 28-
joint disease activity score; WBC white blood cells. 
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When the participants were classified into two 
groups based on blood pressure (Table 2), the 
Pearson’s correlation analysis demonstrated 
significant positive correlation of ESR, CRP, WBC 
values and DAS-28 with systolic blood pressure in 
hypertensive patients, while anti-CCP values were in 
a significant positive correlation only with diastolic 
blood pressure. Pearson’s correlation analysis 
indicated significant positive correlation between ESR, 
WBC count and DAS-28 with systolic blood pressure 
in normotensive patients. It is noteworthy, that age 
was positively correlated to blood pressure only in 
normotensive patients.  
 
 
Discussion 
 
This cross-sectional study showed the 
prevalence of arterial hypertension to be 44.13%: 
43.26% in women and 47.36% in men with RA. The 
main findings of the present study were significantly 
higher levels of surrogate markers of inflammation 
and higher DAS-28 scores among the hypertensive 
compared to normotensive early RA patients; in 
addition, all the study variables were significantly 
correlated with both systolic and diastolic blood 
pressure.  
Several studies showed increased risk for 
CVD and increased morbidity and mortality in RA 
patients compared to non-RA patients [5-9]. An 
association between the inflammation, atherosclerosis 
and hypertension in RA and non-RA populations is 
observed in several prior studies [10-14, 22]. A recent 
study of Innala et al. [20] reported considerable 
comorbidity, especially arterial hypertension, among 
early RA patients at the time of the disease onset, 
emphasizing the importance of inflammation in the 
occurrence of comorbidities. In this context is a Greek 
cohort study of Serelis et al. [21] who concluded that 
hypertension is an important risk factor for CVD 
development among RA patients and highlight the 
importance of strict control of hypertension in RA 
patients. Similarly, Panoulas et al. [22] reported 
increased prevalence of arterial hypertension in RA 
patients; in addition, authors, reported that 
hypertension is underdiagnosed and undertreated, 
especially in older RA patients.  
Our findings are partially in agreement with 
the findings of the Karvounaris et al. [24] and Karakoç 
et al. [25] in observing a significant correlation 
between blood pressure values and the DAS-28 
score. Another recently published study of Hamamoto 
et al. [26] reported an association between RA 
disease activity and increments of nocturnal blood 
pressure.  
Nevertheless, our findings are in 
disagreement with the findings of Panoulas et al. [21] 
and Manavathongchai et al. [27] who failed to find a 
significant association between generalized systemic 
inflammation, as measured by CRP, ESR and DAS-28 
score, and arterial hypertension in RA patients; 
however, the latter study reported that the most likely 
pathogenic mechanisms of hypertension in RA involve 
fat and vascular homeostasis.  
A limitation of the current study is the fact that 
we didn’t account for medications used to treat RA 
(particularly NSAIDS and glucocorticoids) that might 
affect blood pressure. Nevertheless, there are studies 
that did not find an association of medications use and 
arterial hypertension in RA patients [21, 26]. The lack 
of a control group without RA for comparison 
purposes is another limitation of our study. 
In conclusion, despite relatively low 
prevalence of hypertension in this study sample, 
presence of significantly higher values of CRP, ESR, 
anti-CCP and DAS-28 in hypertensive patients 
indicate that inflammation is associated with an 
increased risk of hypertension. Early RA patients 
should be screened for arterial hypertension and 
appropriate early treatment of hypertension alongside 
with early treatment of RA should be considered in 
order to improve the overall outcome in RA.  
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